Go to deals
Healthcare

Poolbeg Pharma has completed an Initial Public Offering on AIM

Poolbeg Pharma Plc has raised funds to develop the company.

Poolbeg Pharma is a clinical-stage, infectious disease pharmaceutical company with a capital light clinical model which aims to develop multiple products faster and more cost-effectively than the conventional biotech model, aspiring to become a one-stop shop for Big Pharma seeking mid-stage products to license or acquire. The company was formed from a spin-out of assets from Open Orphan Plc and is headquartered in London, UK.

Oaklins Cavendish’s sister firm finnCap, based in the UK, in its role as IPO advisor, assisted Poolbeg Pharma’s management team and shareholders all the way from the start to the successful completion of the IPO. During this process, the team initiated and advised on many aspects, including, among others, securing commitments from investors, asset spin out deal structuring, EIS eligibility, and the IPO pricing and sizing.

Service
Funding, debt advisory & ECM
Parties

Talk to the deal team

 Stuart  Andrews

Stuart Andrews

Managing Director

London, United Kingdom
Oaklins Cavendish
 Christopher  Raggett

Christopher Raggett

Partner

London, United Kingdom
Oaklins Cavendish

Related deals

SulAmérica and Rede D’Or São Luiz have announced a combination
Financial Services | Healthcare

SulAmérica and Rede D’Or São Luiz have announced a combination

SulAmérica (B3:SULA11), a leading insurance company in Brazil, has announced a combination with Rede D’Or São Luiz S.A. (B3:RDOR3), the largest Brazilian hospital network. The companies had a combined market value of approximately US$21 billion on 18 February 2022.

Learn more
Serenis and three other independent clinics have acquired Clinique du Chateau de Vernhes
Private Equity | Healthcare

Serenis and three other independent clinics have acquired Clinique du Chateau de Vernhes

Groupe Serenis and three other independent clinics have acquired Clinique du Chateau de Vernhes from the funding family.

Learn more
Biosynex has acquired Para’kito
Healthcare

Biosynex has acquired Para’kito

Biosynex has acquired Para’kito, operated by Hong-Kong based Evergreen Land Ltd. The transaction includes assets and IP and the exclusive right to commercialize the brand in Europe, Africa and South America.

Learn more